&nbsp;

Apr 2024

Drug

ramucirumab

Other Name(s): Cyramza®

Quick Link(s):

Mar 2023

Drug

blinatumomab

Other Name(s): Blincyto®

Quick Link(s):

Nov 2024

Drug

daratumumab

Other Name(s): Darzalex®

Quick Link(s):

Jan 2023

Regimen

ALDE(Intralesional)

Cancer Type:

Skin,

Melanoma

Intent: Palliative, Curative

Funding:

New Drug Funding Program

Aldesleukin (interleukin-2) - In-Transit Metastases from Melanoma

Drugs Used:

aldesleukin

Quick Link(s):

Regimen Monograph

May 2019

Regimen

TEMS

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

New Drug Funding Program

Temsirolimus - Metastatic Renal Cell Carcinoma

Drugs Used:

temsirolimus

Quick Link(s):

Regimen Monograph

Jun 2024

Regimen

CYCLDOCE; CYCLDOCE+TRAS

Cancer Type:

Breast

Intent: Adjuvant

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph, Patient Info Sheet (CYCLDOCE)

Jan 2024

Regimen

NPAC

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Nab-Paclitaxel - Metastatic Breast Cancer

Drugs Used:

nab-PACLitaxel

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

AZCT

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML),

Myelodysplastic Syndrome (MDS),

Myeloproliferative Neoplasms (MPNs)

Intent: Palliative

Funding:

New Drug Funding Program

Azacitidine - Intermediate-2 and high-risk myelodysplastic syndrome (MDS)

New Drug Funding Program

Azacitidine - Acute Myeloid Leukemia (AML)

New Drug Funding Program

Azacitidine - Acute Myeloid Leukemia (AML) Greater Than 30% Blasts

Drugs Used:

azaCITIDine

Quick Link(s):

Regimen Monograph

Jul 2023

Regimen

BMP

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Previously Untreated - Multiple Myeloma

ODB - General Benefit

melphalan - oral tablets

ODB - General Benefit

prednisone

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2019

Regimen

BORT

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Relapsed or Refractory Multiple Myeloma

ODB - General Benefit

dexamethasone

Drugs Used:

bortezomib,

dexamethasone

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

CAPECISP+TRAS

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer

ODB - General Benefit

capecitabine

Drugs Used: